Femasys’ (FEMY) “Buy” Rating Reiterated at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, Chardan Capital dropped their price objective on shares of Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Femasys Stock Performance

Shares of Femasys stock traded down $0.10 during trading on Tuesday, hitting $1.07. 210,182 shares of the stock were exchanged, compared to its average volume of 333,051. Femasys has a 1-year low of $0.73 and a 1-year high of $2.40. The stock has a market capitalization of $23.68 million, a price-to-earnings ratio of -1.28 and a beta of -2.83. The company has a fifty day moving average price of $1.17 and a 200-day moving average price of $1.15. The company has a current ratio of 6.47, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43.

Institutional Investors Weigh In On Femasys

An institutional investor recently bought a new position in Femasys stock. Aljian Capital Management LLC acquired a new position in shares of Femasys Inc. (NASDAQ:FEMY) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned 0.11% of Femasys at the end of the most recent reporting period. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.